NVST Stock Analysis: Envista Holdings | NYSE

Dental Implants, Orthodontic Systems, Dental Imaging, Infection Prevention

Total Rating 61

Safety 86

Buy Signal -0.42

Medical Instruments & Supplies
Industry Rotation: -0.9

Market Cap: 4.01B
Avg Turnover: 78.3M

Risk 3d forecast

Volatility39.0%

VaR 5^th Pctl6.34%

VaR vs Median-1.38%

Reward TTM

Sharpe Ratio0.74

Rel. Str. IBD35.4

Rel. Str. Peer Group32.3 pctl

Character TTM

Beta1.283

Beta Downside1.387

Hurst Exponent0.496

Choppyness61.3%

Drawdowns 3y

Max DD42.00%

CAGR/Max DD0.13

CAGR/Mean DD0.27

EPS (Earnings per Share)

EPS CAGR: 7.73%
EPS Trend: 22.8%

Last SUE: 2.60
Qual. Beats: 2

Revenue

Rev. CAGR: 5.05%
Rev. Trend: 83.7%

Last SUE: 0.12
Qual. Beats: 0

Warnings

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 7 years of data

Jan +1.6% 19

Feb -0.0% 2

Mar +0.1% 2

Apr -4.6% 54

May -2.1% 0

Jun -3.0% 0

Jul +1.1% 18

Aug -4.5% 21

Sep -7.5% 42

Oct +1.0% 16

Nov +2.7% 19

Dec +5.1% 19

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: NVST Envista Holdings

Envista Holdings Corporation (NYSE: NVST) is a Brea, California-based dental products company that develops, manufactures, markets, and sells dental products across the United States, China, and international markets. The company operates through two reportable segments: Specialty Products & Technologies, which covers dental implants, guided surgery, biomaterials, prosthetics, and orthodontic products (including clear aligners and digital treatment software); and Equipment & Consumables, which provides dental imaging systems, endodontic systems, restorative materials, impression materials, bonding agents, and infection prevention products.

The company markets its products under a broad portfolio of established brands, including Nobel Biocare, Ormco, Spark, and Damon in the specialty segment, and Dexis, Kerr, Metrex, Sybron Endo, and CaviWipes in the equipment and consumables segment. Customers include oral surgeons, prosthodontists, periodontists, general dentists, dental offices, clinics, and hospitals. Envista was incorporated in 2018 and completed its IPO in September 2019.

As a Health Care Equipment company (per GICS classification), Envista operates a multi-brand, business-to-business distribution model that sells consumables, equipment, and specialty solutions to dental professionals worldwide, with its product mix spanning consumable supplies, capital equipment, and digital dental software platforms.

Headlines to Watch Out For

China dental implant and equipment demand recovery drives segment revenue
Spark clear aligners growth pressures Align Technology market share
Brea-headquartered Envista expands Specialty Products margin through premium implant brands
FX headwinds and pricing competition compress Equipment & Consumables margins

Piotroski VR-10 (Strict) 6.5

Net Income: 633.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.34 > 1.0
NWC/Revenue: 41.19% < 20% (prev 42.97%; Δ -1.78% < -1%)
CFO/TA 0.05 > 3% & CFO 301.8m > Net Income 633.6m
Net Debt (580.4m) to EBITDA (849.8m): 0.68 < 3
Current Ratio: 2.45 > 1.5 & < 3
Outstanding Shares: last quarter (163.4m) vs 12m ago -4.05% < -2%
Gross Margin: 55.97% > 18% (prev 55.48%; Δ 0.49% > 0.5%)
Asset Turnover: 51.15% > 50% (prev 46.47%; Δ 4.69% > 0%)
Interest Coverage Ratio: 21.46 > 6 (EBIT TTM 733.8m / Interest Expense TTM 34.2m)

Altman Z'' 3.64

A: 0.21 (Total Current Assets 2.00b - Total Current Liabilities 816.3m) / Total Assets 5.61b
B: 0.03 (Retained Earnings 160.3m / Total Assets 5.61b)
C: 0.13 (EBIT TTM 733.8m / Avg Total Assets 5.63b)
D: 1.22 (Book Value of Equity 3.09b / Total Liabilities 2.52b)
Altman-Z'' = 3.64 = AA

Beneish M -2.97

DSRI: 1.01 (Receivables 448.5m/405.9m, Revenue 2.88b/2.62b)
GMI: 0.99 (GM 55.48% / 55.97%)
AQI: 0.97 (AQ_t 0.56 / AQ_t-1 0.58)
SGI: 1.10 (Revenue 2.88b / 2.62b)
TATA: 0.06 (NI 633.6m - CFO 301.8m) / TA 5.61b)
Beneish M = -2.97 (Cap -4..+1) = A

What is the price of NVST shares?

As of November 09, 2026, the stock is trading at USD 25.17 with a total of 3,234,799 shares traded. Over the past week, the price has changed by +7.06%, over one month by +8.17%, over three months by -8.07% and over the past year by +29.21%.

Current recommended Stop Loss: 23.90 (which is 5% or 1.2 ATR below the current price).

Is NVST a buy, sell or hold?

Envista Holdings has received a consensus analysts rating of 3.80. Therefore, it is recommended to hold NVST.

StrongBuy: 5
Buy: 2
Hold: 8
Sell: 0
StrongSell: 0

What are the forecasts/targets for the NVST price?

Analysts Target Price	28.7	14%

Envista Holdings (NVST) - Fundamental Data Overview as of 07 November 2026

Market Cap USD = 4.01b (4.01b USD * 1.0 USD.USD)
P/E Trailing = 47.0943
P/E Forward = 16.8067
P/S = 1.4035
P/B = 1.2933
Revenue TTM = 2.88b USD
EBIT TTM = 733.8m USD
EBITDA TTM = 849.8m USD
Long Term Debt = 1.45b USD (from longTermDebt, last fiscal year)
Short Term Debt = 37.9m USD (from shortTermDebt, last quarter)
Debt = 1.74b USD (from shortLongTermDebtTotal, last quarter) + Leases 151.7m
Net Debt = 580.4m USD (calculated: Debt 1.74b - CCE 1.16b)
Enterprise Value = 4.59b USD (4.01b + Debt 1.74b - CCE 1.16b)
Interest Coverage Ratio = 21.46 (Ebit TTM 733.8m / Interest Expense TTM 34.2m)
EV/FCF = 18.96x (Enterprise Value 4.59b / FCF TTM 242.0m)
FCF Yield = 5.27% (FCF TTM 242.0m / Enterprise Value 4.59b)
FCF Margin = 8.41% (FCF TTM 242.0m / Revenue TTM 2.88b)
Net Margin = 22.01% (Net Income TTM 633.6m / Revenue TTM 2.88b)
Gross Margin = 55.97% ((Revenue TTM 2.88b - Cost of Revenue TTM 1.27b) / Revenue TTM)
Gross Margin QoQ = 57.93% (prev 55.72%)
Tobins Q-Ratio = 0.82 (Enterprise Value 4.59b / Total Assets 5.61b)
Interest Expense / Debt = 1.97% (Interest Expense 34.2m / Debt 1.74b)
Taxrate = 7.42% (50.8m / 684.4m)
NOPAT = 679.3m (EBIT 733.8m * (1 - 7.42%))
Current Ratio = 2.45 (Total Current Assets 2.00b / Total Current Liabilities 816.3m)
Debt / Equity = 0.56 (Debt 1.74b / totalStockholderEquity, last quarter 3.09b)
Debt / EBITDA = 0.68 (Net Debt 580.4m / EBITDA 849.8m)
Debt / FCF = 2.40 (Net Debt 580.4m / FCF TTM 242.0m)
Total Stockholder Equity = 3.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.26% (Net Income 633.6m / Total Assets 5.61b)
RoE = 20.52% (Net Income TTM 633.6m / Total Stockholder Equity 3.09b)
RoCE = 16.18% (EBIT 733.8m / Capital Employed (Equity 3.09b + L.T.Debt 1.45b))
RoIC = 14.49% (NOPAT 679.3m / Invested Capital 4.69b)
WACC = 7.49% (E(4.01b)/V(5.75b) * Re(9.95%) + D(1.74b)/V(5.75b) * Rd(1.97%) * (1-Tc(0.07)))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.44 | Cagr: -2.28%
[DCF] Terminal Value 74.31% ; FCFF base≈250.2m ; Y1≈234.8m ; Y5≈217.2m
[DCF] Fair Price = 17.74 (EV 3.43b - Net Debt 580.4m = Equity 2.85b / Shares 160.6m; r=8.35% [WACC [floored]]; 5y FCF grow -7.81% → 2.50% )
EPS Correlation: 22.80 | EPS CAGR: 7.73% | SUE: 2.60 | # QB: 2
Revenue Correlation: 83.70 | Revenue CAGR: 5.05% | SUE: 0.12 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.39 | Chg30d=-0.85% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=1.53 | Chg30d=-0.22% | Revisions=-62% | GrowthEPS=+28.5% | GrowthRev=+5.8%
EPS next Year (2027-12-31): EPS=1.66 | Chg30d=-0.50% | Revisions=-55% | GrowthEPS=+8.5% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: -61% (up=2, down=13)